Skip to main content
Premium Trial:

Request an Annual Quote

NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation

NEW YORK (GenomeWeb) – Lifecode today announced a previously undisclosed Series A Round in financing that raised $20.5 million. The firm also said it received accreditation from the College of American Pathologists. 

The $20.5 million financing was led by Sequoia Capital, Mayo Clinic, and Mayo Ventures. Based in Foster City, Calif., and previously called Silicon Valley Biosystems, Lifecode was founded two years ago and is developing next-generation sequencing-based cancer assays to detect and interpret genomic alterations in patient tumor samples.

Last month the company launched its Pan Cancer Somatic Panel to select physicians in the US with plans to commercialize it more broadly in the spring. 

Lifecode received CAP accreditation following an inspection of its staff qualifications, equipment, quality controls, safety programs, records, and overall management of clinical laboratories. In June 2013, Lifecode received CLIA certification from the California Department of Public Health.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.